Align Technology stock (US0162551016): Officer discloses initial holdings of 2,106 shares

Align Technology officer Jitse Marree filed an initial Form 3 statement revealing direct ownership of 2,106 common shares, including restricted and market stock units, as reported in an SEC filing.

Align Technology officer Jitse Marree filed an initial statement of beneficial ownership on May 12, 2026, disclosing direct holdings of 2,106 shares of common stock, alongside 226 restricted stock units and 1,837 market stock units, according to StockTitan as of 05/12/2026. This Form 3 filing marks the first public disclosure of these holdings for the executive at the Nasdaq-listed orthodontics leader.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Align Technology, Inc.
• Sector/industry: Healthcare / Orthodontics
• Headquarters/country: United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Invisalign clear aligners, iTero scanners
• Home exchange/listing venue: Nasdaq (ALGN)
• Trading currency: USD

Align Technology: core business model

Align Technology develops and markets Invisalign clear aligner systems for orthodontic treatment, alongside intraoral scanning solutions via its iTero scanners. The company operates a direct-to-consumer model in orthodontics, partnering with dentists and orthodontists worldwide to deliver customized aligners produced at scale in Mexico and other facilities. This asset-light approach emphasizes digital workflows, from scanning to treatment planning via the ClinCheck software.

Founded in 1997 and headquartered in Tempe, Arizona, Align Technology went public on Nasdaq in 2001. Its business spans consumer-facing orthodontics and professional digital dentistry tools, with Invisalign driving the majority of revenue. The firm serves over 20 million patients cumulatively, highlighting its dominance in the shift from traditional braces to discreet aligners popular among US adults and teens.

Main revenue and product drivers for Align Technology

Invisalign systems account for approximately 80-85% of revenue, with cases starting at around 20 aligners per patient and generating recurring income from refinements. iTero scanners contribute through hardware sales, software subscriptions, and services, enabling digital impressions that integrate with Invisalign planning. Clear aligner volumes have grown steadily, supported by expanded indications for teens and remote monitoring via the myAlign app.

Geographically, the Americas represent over 50% of sales, with strong US market penetration where Invisalign holds a leading share in direct clear aligner sales. International growth in EMEA and APAC bolsters diversification, per the company's Q4 2025 report published in early 2026. US investors track Align for its exposure to elective dental procedures resilient to economic cycles.

Industry trends and competitive position

The orthodontics market shifts toward digital and clear aligners, valued at $5-6 billion globally with 10%+ CAGR through 2030 per sector reports. Align Technology commands over 80% US market share in clear aligners, fending off competitors like SmileDirectClub (defunct) and emerging direct-to-consumer players via provider network scale and FDA-cleared technology. iTero's 70%+ share in digital scanners strengthens ecosystem lock-in.

Why Align Technology matters for US investors

Listed on Nasdaq as ALGN, Align Technology offers US investors pure-play exposure to medtech innovation in consumer healthcare. With 70%+ of revenue from North America, it benefits from rising adult orthodontics demand amid aesthetic dentistry trends. Its Nasdaq listing ensures liquidity and visibility, with shares trading in USD and quarterly SEC filings providing transparency for retail portfolios.

Conclusion

The recent Form 3 filing by officer Jitse Marree underscores ongoing executive alignment with shareholders at Align Technology, amid a business model centered on Invisalign dominance and digital dentistry growth. While insider disclosures provide insight into compensation structures, the company's US-centric revenue and Nasdaq listing maintain relevance for American investors tracking medtech trends. Market dynamics in orthodontics continue to favor established players like Align.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.